Xeris Pharmaceuticals | XERS - Operating Expenses


Xeris Pharmaceuticals reported $75.21M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Celltrion KRW 119.22B 21.46B Mar/2026
Cspc Pharmaceutical CNY 5.91B 512.77M Dec/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Divis Laboratories Ltd INR 19.51B 660M Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Kangmei Pharma CNY 1.09B 304.02M Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Organigram Holdings CAD 69.59M 14.08M Mar/2026
Ovoca Bio EUR 173K 990K Dec/2025
Pacira USD 180.54M 7.79M Jun/2026
Perrigo USD 290.5M 645.1M Jun/2026
Pharma Mar EUR 51.01M 8.73M Jun/2026
Qiagen NV USD 393.64M 17.95M Jun/2026
Sartorius EUR 747.8M 9.4M Jun/2026
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Tilray USD 237.52M 17.34M Sep/2025
Zealand Pharma A/S 573M 202.97M Mar/2026
Zz Pientze Pharmaceu CNY 1.45B 431.06M Jun/2026